Prognose

Das durchschnittliche Kursziel der Analysten beträgt +20,46€(+166,75%). Der Median liegt bei +18,41€(+140,03%).

Kaufen	12
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	14 / 18
Levermann-Strategie	-6 / 13

News

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment, most often due to lack of efficacy; inability to wake up was most common reason for missing second nightly dose -- DUBLIN, April 17, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and nference , a health tech company dedicated to making biomedical data computable, today announced the publication of real-world data on comorbidities and treatment patterns of people with narcolepsy treated versus not treated with immediate-release sodium oxybate.» Mehr auf globenewswire.com
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 48,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.» Mehr auf globenewswire.com
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Avadel Pharmaceuticals ADR einen Umsatz von 48,44 Mio€ und ein Nettoeinkommen von −4,85 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	+48,44 Mio	175,30%
Bruttoeinkommen	+43,82 Mio	158,22%
Nettoeinkommen	−4,85 Mio	81,39%
EBITDA	−1,53 Mio	93,62%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+741,33 Mio€
Anzahl Aktien	96,63 Mio
52 Wochen-Hoch/Tief	+16,74€ - +5,59€
Dividenden	Nein
Beta	1,52
KGV (PE Ratio)	−17,27
KGWV (PEG Ratio)	−0,53
KBV (PB Ratio)	+11,42
KUV (PS Ratio)	+5,00

Unternehmensprofil

Avadel Pharmaceuticals plc ist als biopharmazeutisches Unternehmen in den Vereinigten Staaten tätig. Sein führender Produktkandidat ist FT218, eine Formulierung von Natriumoxybat, die sich in einer klinischen Phase-3-Studie zur Behandlung von exzessiver Tagesschläfrigkeit und Kataplexie bei Erwachsenen mit Narkolepsie befindet. Das Unternehmen war früher unter dem Namen Flamel Technologies SA bekannt und änderte im Januar 2017 seinen Namen in Avadel Pharmaceuticals plc. Avadel Pharmaceuticals plc wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Dublin, Irland.